Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05817045 · ClinicalTrials.gov registry record · NA

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

A NA study of COVID-19, sponsored by EmitBio.

Completed
Registry status
NA
Development phase
330
Enrollment target
20
Study locations

NCT05817045 is a NA study of COVID-19 that has completed, run by EmitBio. The registered enrollment target is 330 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05817045, a NA study of COVID-19, has completed, sponsored by EmitBio.

COMPLETED
Registry status
NA
Development phase
330 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.

Conditions Studied

COVID-19

Interventions

  • DEVICE Sham
  • DEVICE RD-X19

Study Locations (20)

California

  • 312 - Smart Cures Clinical Research - Anaheim
  • 313 - Benchmark Southern California - Colton
  • 307 - Ark Clinical Research - Long Beach
  • 329 - Valley Clinical Trials - Northridge
  • 348 - San Francisco Research Institute - San Francisco
  • 328 - Mills Clinical Research - West Hollywood

Florida

  • 305 - Indago Research and Health Center - Hialeah
  • 321 - Helios Clinical Research - Kissimmee - Kissimmee
  • 310 - Accel Research Sites - St. Petersburg - Largo
  • 306 - Miami Clinical Research - Miami

Illinois

  • 349 - Chicago Medical Research - Chicago
  • 333 - Prime Global Research Inc. - Chicago
  • 331 - Chicago Clinical Research Institute - Chicago

Arizona

  • 322 - Desert Clinical Research/CCT Research - Mesa
  • 347 - Velocity Clinical Research - Phoenix

Georgia

  • 341 - Lifeline Primary Care / CCT Research - Lilburn

Iowa

  • 345 - The Iowa Clinic/Avacare Legacy - West Des Moines

Kentucky

  • 337 - Versailles Family Medicine/CCT Research - Versailles

Louisiana

  • 346 - Benchmark Research - Metairie

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2023-04-21
Est. Completion 2024-06-30
Phase NA

Sponsor

EmitBio

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05817045

The ClinicalTrials.gov registry entry for NCT05817045 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is EmitBio, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.

NCT05817045 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05817045 about?

NCT05817045 is a clinical study titled "Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19". This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.

What is the current status of trial NCT05817045?

This trial is currently completed. It is a NA study. The enrollment target is 330 participants. The study started on 2023-04-21. Estimated completion is 2024-06-30.

What conditions does trial NCT05817045 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT05817045?

The interventions under investigation include: Sham (DEVICE), RD-X19 (DEVICE).

Who is sponsoring clinical trial NCT05817045?

This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05817045 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.